Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Reduced E-cadherin expression is a predictor of lower overall survival and metastatic disease in invasive ductal breast cancer (CROSBI ID 212987)

Prilog u časopisu | izvorni znanstveni rad

Eljuga, Domagoj ; Bulić, Krešimir ; Petrovečki, Marko ; Bali, Vedrana ; Ozimec, Elizabeta ; Jakić Razumović, Jasminka Reduced E-cadherin expression is a predictor of lower overall survival and metastatic disease in invasive ductal breast cancer // Oncology research and treatment, 35 (2012), 7/8; 414-418. doi: 10.1159/000341071

Podaci o odgovornosti

Eljuga, Domagoj ; Bulić, Krešimir ; Petrovečki, Marko ; Bali, Vedrana ; Ozimec, Elizabeta ; Jakić Razumović, Jasminka

engleski

Reduced E-cadherin expression is a predictor of lower overall survival and metastatic disease in invasive ductal breast cancer

E-cadherin, a transmembrane adhesion molecule, is implicated in the development of many solid tumors as well as in the acquisition of metastatic potential of epithelial tumors. Its clinical use has yet to be established. The prognostic value of E-cadherin expression in 134 invasive ductal breast carcinoma patients over a 10-year follow-up period was investigated. Additionally, the correlation between E-cadherin expression and other traditional prognostic factors was investigated. A statistically significant influence on overall survival was found for estrogen receptor, tumor size, histological and nuclear grade, HER2, lymph node involvement, vascular invasion, proliferative index, and E-cadherin. E-cadherin expression had a significant impact on overall survival and development of metastases in the group of patients not receiving chemotherapy, while it had no such effect in the group of patients who received chemotherapy. We conclude that determination of E-cadherin expression can be used as an adjunct in selecting patients who may benefit from adjuvant chemotherapy in the presence of otherwise favorable prognostic factors

breast cancer e-cadherin metastatic disease overal survival

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

35 (7/8)

2012.

414-418

objavljeno

2296-5270

10.1159/000341071

Povezanost rada

Kliničke medicinske znanosti

Poveznice